Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

Comparative Protein Modelling by Satisfaction of Spatial Restraints

Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977 · see citing works

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works

<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · see citing works

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · see citing works

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works

Development of Novel Fluorescence Probes That Can Reliably Detect Reactive Oxygen Species and Distinguish Specific Species

Setsukinai, K.-I., Urano, Y., Kakinuma, K., Majima, H. J., & Nagano, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209264200 · Cited by 1,301 · see citing works

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · see citing works

<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · see citing works

IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication

Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Käyser, S., Zucknick, M., Götze, K. S. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 803 · see citing works

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Marcucci, G., Maharry, K. S., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763 · see citing works

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736 · see citing works

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · see citing works

( <i>R</i> )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · see citing works

Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b

Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640 · see citing works

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513 · see citing works

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

Cairns, R. A., Iqbal, J., Lemonnier, F., Küçük, C., de Leval, L., Jaïs, J., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 505 · see citing works

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice

Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418 · see citing works

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

Abbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A. M., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 394 · see citing works

Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML

Sallmyr, A., Fan, J., Datta, K., Kim, K.-T., Grosu, D., Shapiro, P. S., Small, D., & Rassool, F. V. (2008) · Blood · doi:10.1182/blood-2007-05-092510 · Cited by 318 · see citing works

Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms

Green, A. R., & Beer, P. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285 · see citing works

Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor

Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O. G., Lübbert, M., Heit, W. F. W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 241 · see citing works

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

Heuser, M., Beutel, G., Krauter, J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-014845 · Cited by 232 · see citing works

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation

Chou, W., Hou, H., Chen, C., Tang, J., Yao, M., Tsay, W., Ko, B.-S., Wu, S., Huang, S., Hsu, S.-C., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253070 · Cited by 204 · see citing works

Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications

Wong, I. H. N., Ng, M. H. L., Huang, D. P., & Lee, J. C. K. (2000) · Blood · doi:10.1182/blood.v95.6.1942 · Cited by 199 · see citing works

Context Dependence of Different Modules for Posttranscriptional Enhancement of Gene Expression from Retroviral Vectors

Schambach, A., Wodrich, H., Hildinger, M., Bohne, J., Kräusslich, H.-G., & Baum, C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0191 · Cited by 194 · see citing works

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Thol, F. R., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O. G., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 193 · see citing works

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

Thol, F. R., Damm, F., Wagner, K., Göhring, G., Schlegelberger, B., Hoelzer, D. F., Lübbert, M., Heit, W. F. W., Kanz, L., Schlimok, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272146 · Cited by 186 · see citing works

MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML

Heuser, M., Argiropoulos, B., Kuchenbauer, F. C., Yung, E., Piper, J., Fung, S., Schlenk, R. F., Döhner, K., Hinrichsen, T., Rudolph, C., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080523 · Cited by 148 · see citing works

Measurement of Urinary d- and l-2-Hydroxyglutarate Enantiomers by Stable-Isotope-Dilution Liquid Chromatography–Tandem Mass Spectrometry after Derivatization with Diacetyl-l-Tartaric Anhydride

Struys, E. A., Jansen, E. E. W., Verhoeven‐Duif, N. M., & Jakobs, C. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.033399 · Cited by 147 · see citing works

NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d ‐2‐hydroxyglutaric aciduria

Kölker, S., Pawlak, V., Ahlemeyer, B., Okun, J. G., Hörster, F., Mayatepek, E., Krieglstein, J., Hoffmann, G. F., & Köhr, G. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02055.x · Cited by 133 · see citing works

Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer

Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 132 · see citing works

Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation

Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 129 · see citing works

D‐2‐hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

Latini, A., Scussiato, K., Rosa, R. B., Llesuy, S., Belló‐Klein, A., Dutra‐Filho, C. S., & Wajner, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02639.x · Cited by 112 · see citing works

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)

Scherr, M., Chaturvedi, A., Battmer, K., Dallmann, I., Schultheis, B. S., Ganser, A., & Eder, M. (2005) · Blood · doi:10.1182/blood-2005-08-3087 · Cited by 111 · see citing works

Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex.

Heuser, M., Yun, H.-Y., Berg, T., Yung, E., Argiropoulos, B., Kuchenbauer, F., Park, G., Hamwi, I., Palmqvist, L., Lai, C., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.020 · Cited by 104 · see citing works

Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation

Heuser, M., Yap, D., Leung, M., de Algara, T. R., Tafech, A., McKinney, S. E., Dixon, J., Thresher, R. R., Colledge, B., Carlton, M. B. L., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162263 · Cited by 101 · see citing works

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal

Heuser, M., Sly, L. M., Argiropoulos, B., Kuchenbauer, F. C., Lai, C. K., Weng, A. P., Leung, M., Lin, G., Brookes, C., Fung, S., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227603 · Cited by 77 · see citing works

NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation

Gurevich, R. M., Aplan, P. D., & Humphries, R. K. (2004) · Blood · doi:10.1182/blood-2003-10-3550 · Cited by 45 · see citing works

Functional role of BAALC in leukemogenesis

Heuser, M., Berg, T., Kuchenbauer, F. C., et al. (2011) · Leukemia · doi:10.1038/leu.2011.228 · Cited by 38 · see citing works

The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia

Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 676 · see citing works

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · see citing works

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 661 · see citing works

The Need for Multi-Omics Biomarker Signatures in Precision Medicine

Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D., & Cox, L. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194781 · Cited by 504 · see citing works

Differentiation therapy revisited

de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462 · see citing works

Isocitrate dehydrogenase mutations in myeloid malignancies

Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. T. (2016) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 348 · see citing works

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

Lee, S., Çelik, S., Logsdon, B. A., Lundberg, S., Martins, T. J., Oehler, V. G., Estey, E. H., Miller, C. P., Chien, S. S., Dai, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02465-5 · Cited by 332 · see citing works

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

Im, A., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M. M. (2014) · Leukemia · doi:10.1038/leu.2014.124 · Cited by 266 · see citing works

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Liu, Y., Sun, Y., Guo, Y., Shi, X., Chen, X., Feng, W., Wu, L., Zhang, J., Yu, S., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81609 · Cited by 260 · see citing works

Wild-type and mutated IDH1/2 enzymes and therapy responses

Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 243 · see citing works

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Golub, D., Iyengar, N. S., Dogra, S., Wong, T., Bready, D., Tang, K., Modrek, A. S., & Placantonakis, D. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00417 · Cited by 231 · see citing works

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

Clark, O., Yen, K. E., & Mellinghoff, I. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1333 · Cited by 205 · see citing works

Isocitrate Dehydrogenase Mutation and ( <i>R</i> )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development

Dang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204 · see citing works

TET proteins and 5‐methylcytosine oxidation in hematological cancers

Ko, M., An, J., Pastor, W. A., Koralov, S. B., Rajewsky, K., & Rao, A. (2014) · Immunological Reviews · doi:10.1111/imr.12239 · Cited by 197 · see citing works

Therapeutic implications of menin inhibition in acute leukemias

Issa, G. C., Ravandi, F., Dinardo, C. D., Jabbour, E. J., Kantarjian, H. M., & Andreeff, M. (2021) · Leukemia · doi:10.1038/s41375-021-01309-y · Cited by 195 · see citing works

Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance

Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K. S., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.016 · Cited by 187 · see citing works

Driver mutations of cancer epigenomes

Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 183 · see citing works

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation

Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 181 · see citing works

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome

Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 170 · see citing works

The Roles of 2-Hydroxyglutarate

Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 152 · see citing works

p53 and metabolism: from mechanism to therapeutics

Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 152 · see citing works

Radioprotection of <i>IDH1</i> -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148 · see citing works

Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment

Justus, C., Sanderlin, E. J., & Yang, L. V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511055 · Cited by 136 · see citing works

Advances in epigenetic therapeutics with focus on solid tumors

Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 133 · see citing works

Targeting DOT1L and HOX Gene Expression in MLL-Rearranged Leukemia and Beyond

Chen, C., & Armstrong, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.012 · Cited by 121 · see citing works

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M

Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 125 · see citing works

The Role of IDH Mutations in Acute Myeloid Leukemia

Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 123 · see citing works

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Chaturvedi, A., Herbst, L., Pusch, S., Klett, L. C., Goparaju, R., Stichel, D., Kaulfuß, S., Panknin, O., Zimmermann, K. C., Toschi, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.46 · Cited by 122 · see citing works

DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis

Ciechomska, M., Roszkowski, L., & Maśliński, W. (2019) · Cells · doi:10.3390/cells8090953 · Cited by 123 · see citing works

An Epigenetic Role of Mitochondria in Cancer

Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 125 · see citing works

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins

Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 110 · see citing works

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 109 · see citing works

IDH1/2but notDNMT3Amutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Debarri, H., Lebon, D., Roumier, C., Cheok, M. H.-C., Marceau‐Renaut, A., Nibourel, O., Geffroy, S., Hélevaut, N., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5645 · Cited by 98 · see citing works

Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia

Mingay, M., Chaturvedi, A., Bilenky, M., Cao, Q., Jackson, L., Hui, T., Moksa, M., Heravi-Moussavi, A., Humphries, R. K., Heuser, M., et al. (2018) · Leukemia · doi:10.1038/leu.2017.171 · Cited by 94 · see citing works

Epigenetics in SLE

Hedrich, C. M. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0685-1 · Cited by 97 · see citing works

5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer

Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 95 · see citing works

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms

Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 96 · see citing works

The Impact of DNA Methylation in Hematopoietic Malignancies

Guillamot, M., Cimmino, L., & Aifantis, I. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.12.006 · Cited by 90 · see citing works

Recent advances of IDH1 mutant inhibitor in cancer therapy

Tian, W., Zhang, W., Wang, Y., Jin, R., Wang, Y., Guo, H., Tang, Y., & Yao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982424 · Cited by 88 · see citing works

Digging deep into “dirty” drugs – modulation of the methylation machinery

Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84 · see citing works

Epigenetics in the hematologic malignancies

Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 83 · see citing works

D-2-Hydroxyglutarate in Glioma Biology

Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 83 · see citing works

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia

Emadi, A., Faramand, R. G., Carter‐Cooper, B., Tolu, S. S., Ford, L. A., Lapidus, R. G., Wetzler, M., Wang, E. S., Etemadi, A., & Griffiths, E. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.23965 · Cited by 78 · see citing works

Chromatin modifiers and the promise of epigenetic therapy in acute leukemia

Greenblatt, S. M., & Nimer, S. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 84 · see citing works

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

Chen, J.-Y., Lai, Y.-S., Tsai, H., Kuo, C.-C., Yen, B. L., Yeh, S., Sun, H. S., & Hung, W.-C. (2016) · Scientific Reports · doi:10.1038/srep32428 · Cited by 73 · see citing works

Mitochondrial dependency in progression of acute myeloid leukemia.

Basak, N., & Banerjee, S. (2015) · Mitochondrion (Amsterdam. Print) · doi:10.1016/j.mito.2015.01.006 · Cited by 61 · see citing works

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2

Ma, R., & Yun, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.068 · Cited by 73 · see citing works

Epigenetics in T‐cell acute lymphoblastic leukemia

Peirs, S., der Meulen, J. V., de Walle, I. V., Taghon, T., Speleman, F., Poppe, B. G., & Vlierberghe, P. V. (2014) · Immunological Reviews · doi:10.1111/imr.12237 · Cited by 72 · see citing works

Investigational cancer drugs targeting cell metabolism in clinical development

Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72 · see citing works

Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation

Wang, E., Zhou, H., Nadorp, B., Cayanan, G., Chen, X., Yeaton, A. H., Nomikou, S., Witkowski, M. T., Narang, S., Kloetgen, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2020.12.005 · Cited by 66 · see citing works

Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

Lambert, M., Alioui, M., Jambon, S., Depauw, S., van Seuningen, I., & David-Cordonnier, M. (2019) · Cancers · doi:10.3390/cancers11060837 · Cited by 58 · see citing works

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 68 · see citing works

Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions

Kim, T. K., Gore, S. D., & Zeidan, A. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.04.003 · Cited by 67 · see citing works

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology

Cantafio, M. E. G., Grillone, K., Caracciolo, D., Scionti, F., Arbitrio, M., Barbieri, V., Pensabene, L., Guzzi, P. H., & Martino, M. T. D. (2018) · Microarrays · doi:10.3390/ht7040033 · Cited by 66 · see citing works

MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis

Trissal, M. C., Wong, T. N., Yao, J.-C., Ramaswamy, R., Kuo, I., Baty, J., Sun, Y., Jih, G. T., Parikh, N., Berrien-Elliott, M. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3592 · Cited by 66 · see citing works

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia

Ogawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58 · see citing works

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials

Sasine, J. P., & Schiller, G. J. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.07.002 · Cited by 58 · see citing works

Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed

Pfohl, U., Pflaume, A., Regenbrecht, M., Finkler, S., Adelmann, Q. G., Reinhard, C., Regenbrecht, C. R. A., & Wedeken, L. (2021) · Cells · doi:10.3390/cells10040928 · Cited by 60 · see citing works

The role of mutations in epigenetic regulators in myeloid malignancies

Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 60 · see citing works

Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia

Sun, Y., Chen, B.-R., & Deshpande, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 52 · see citing works

The Warburg effect: a balance of flux analysis

Vaitheesvaran, B., Xu, J., Yee, J. K., Lu, Q., Go, V. L. W., Xiao, G. G., & Lee, W. N. (2014) · Metabolomics · doi:10.1007/s11306-014-0760-9 · Cited by 58 · see citing works

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 57 · see citing works

Epigenetics in myelodysplastic syndromes

Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61 · see citing works

Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer

Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 54 · see citing works

A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3

Garama, D. J., Harris, T. J., White, C. L., Rossello, F. J., Abdul‐Hay, M., Gough, D. J., & Levy, D. E. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00541-15 · Cited by 55 · see citing works

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma

Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 54 · see citing works

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis

Kattih, B., Shirvani, A., Klement, P., Garrido, A. M., Gabdoulline, R. R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., Thol, F. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01043-x · Cited by 54 · see citing works

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia

Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 52 · see citing works

Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects

Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 48 · see citing works

Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications

Sportoletti, P., Varasano, E., Rossi, R., Mupo, A., Tiacci, E., Vassiliou, G. S., Martelli, M. P., & Falini, B. (2014) · Leukemia · doi:10.1038/leu.2014.257 · Cited by 48 · see citing works

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia

Fathi, A. T., Wander, S. A., Faramand, R. G., & Emadi, A. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.002 · Cited by 48 · see citing works

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 48 · see citing works

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

Pastore, F., & Levine, R. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 50 · see citing works

Glial Progenitors as Targets for Transformation in Glioma

Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 46 · see citing works

Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications

Kaina, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237442 · Cited by 45 · see citing works

Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism

DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S., & Dang, L. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.007 · Cited by 44 · see citing works

The Impact of Epigenetic Modifications in Myeloid Malignancies

Venney, D., Mohd-Sarip, A., & Mills, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095013 · Cited by 41 · see citing works

Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas

Li-Chang, H. H., Kasaian, K., Ng, Y., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1021-7 · Cited by 42 · see citing works

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

Ferret, Y., Boissel, N., Hélevaut, N., Madic, J., Nibourel, O., Marceau‐Renaut, A., Bucci, M., Geffroy, S., Celli‐Lebras, K., Castaigné, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183525 · Cited by 43 · see citing works

Enasidenib and ivosidenib in AML

Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42 · see citing works

Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging

Li, D., Patel, C. B., Xu, G., Iagaru, A. H., Zhu, Z., Zhang, L., & Cheng, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592389 · Cited by 42 · see citing works

Stem cell origin of myelodysplastic syndromes

Elias, H. K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A. K., & Steidl, U. G. (2013) · Oncogene · doi:10.1038/onc.2013.520 · Cited by 39 · see citing works

Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer

Sahu, R., Mishra, R., Kumar, R., Salahuddin, S., Majee, C., Mazumder, A., & Kumar, A. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210614162031 · Cited by 39 · see citing works

Molecular Approaches to Treating Pediatric Leukemias

Kuhlen, M., Klusmann, J., & Hoell, J. I. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00368 · Cited by 38 · see citing works

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Chaturvedi, A., Gupta, C., Gabdoulline, R. R., Borchert, N. M., Goparaju, R., Kaulfuß, S., Görlich, K., Schottmann, R., Othman, B., Welzenbach, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.236992 · Cited by 37 · see citing works

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting

Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 38 · see citing works

Mechanistic aspects of epigenetic dysregulation in SLE

Hedrich, C. M. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.002 · Cited by 37 · see citing works

Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia

Kao, H., Liang, D., Wu, J., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.06.002 · Cited by 36 · see citing works

The mechanistic role of DNA methylation in myeloid leukemogenesis

Jasielec, J. K., Saloura, V., & Godley, L. A. (2014) · Leukemia · doi:10.1038/leu.2014.163 · Cited by 36 · see citing works

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics

Falini, B., Sportoletti, P., Brunetti, L., & Martelli, M. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13409 · Cited by 37 · see citing works

Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases

Ciechomska, M., & O’Reilly, S. (2016) · Mediators of Inflammation · doi:10.1155/2016/9607946 · Cited by 36 · see citing works

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Platt, M. Y., Fathi, A. T., Borger, D. R., Brunner, A. M., Hasserjian, R. P., Balaj, L., Lum, A. M., Yip, S. S. F., Dias-Santagata, D. C., Zheng, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.004 · Cited by 35 · see citing works

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Mosna, F., Capelli, D., & Gottardi, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6060057 · Cited by 35 · see citing works

Orphan drug designation for pracinostat, volasertib and alvocidib in AML

Bose, P., & Grant, S. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.007 · Cited by 35 · see citing works

Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis

Niu, N., Ye, J., Hu, Z., Zhang, J., & Wang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087076 · Cited by 32 · see citing works

Metabolomics in Cancer Biomarker Research

Wang, X., Chen, S., & Jia, W. P. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0074-x · Cited by 32 · see citing works

The Yin and Yang of cancer genes

Bashyam, M. D., Animireddy, S., Bala, P., Naz, A., & George, S. A. (2019) · Gene · doi:10.1016/j.gene.2019.04.025 · Cited by 32 · see citing works

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions

Upadhyay, V. A., Brunner, A. M., & Fathi, A. T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.003 · Cited by 32 · see citing works

Rational Combinations of Targeted Agents in AML

Bose, P., & Grant, S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040634 · Cited by 30 · see citing works

Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution

Bravo, G. M., Lee, E., Merchán, B., Kantarjian, H. M., & Garcia‐Manero, G. (2014) · British Journal of Haematology · doi:10.1111/bjh.12957 · Cited by 30 · see citing works

The Novel Symbiotic Phenotype of Enhanced-Nodulating Mutant of Lotus japonicus: astray Mutant is an Early Nodulating Mutant with Wider Nodulation Zone

Nishimura, R., Ohmori, M., & Kawaguchi, M. (2002) · Plant and Cell Physiology · doi:10.1093/pcp/pcf098 · Cited by 60 · see citing works

Studies on a Temperature-sensitive Irreparable Mutant of Neurospora Crassa

Kuwana, H. (1960) · The Japanese Journal of Genetics · doi:10.1266/jjg.35.49 · Cited by 11 · see citing works

New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status

Shibahara, I., Sonoda, Y., Kanamori, M., Saito, R., Kumabe, T., & Tominaga, T. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-011-0050-4 · Cited by 7 · see citing works

Isocitrate dehydrogenase 1 mutations and human gliomas

Yu, J. (2011) · International Journal of Pathology and Clinical Medicine

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies

Ikota, H., Nobusawa, S., Arai, H., Kato, Y., Ishizawa, K., Hirose, T., & Yokoo, H. (2015) · Brain Tumor Pathology · doi:10.1007/s10014-015-0222-8 · Cited by 30 · see citing works